ARDT NYSE Week ended 31 Jul 2026

Weekly Investor Report

Ardent Health Partners, Inc. · Healthcare · Medical Care Facilities

Open interactive chart View report data
Latest close 10.67 USD
0.3% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 13.4% above the Trend Line and sits at 38.1% of its 52-week range. The latest completed week returned 0.3%, after a -0.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is inexpensive relative to peers. Options positioning is mixed with 37/100 conviction, while the latest news-sentiment score is 48/100. Near-term considerations: earnings are due in 1d.

Setup score 38 out of 100
Latest Close 10.67 USD 31 Jul 2026
1W Return 0.3% latest completed week
4W Return -0.8% short-term follow-through
12W Return 5.5% quarterly tape
Trend Breadth 21.2% 11 of 52 weeks active
Volume Ratio 1.1x vs 13-week average
What is working
  • The trend backdrop is active with a 6-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 44.18% based on similar historical setup states.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.3% Latest completed week; four-week move -0.8%. Indicator stack 32/66 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 44.18% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Mixed 37/100 conviction; expected move 31.2%. News sentiment 48/100 54 relevant articles in the latest sentiment read. Event risk 1d Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 13.4% above the Trend Line and sits at 38.1% of its 52-week range. The latest completed week returned 0.3%, after a -0.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.1x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.4512-week average 0.31

12-week confirmation

Trend active8/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.45Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -0.8% over four weeks, 5.5% over 12 weeks, and 4.4% over one year. The current trend has remained active for 6 consecutive weeks.

Performance by holding period

1W0.3%
4W-0.8%
12W5.5%
26W30.6%
52W4.4%
Active trend streak6 weeks
Active weeks in one year11
Trend breadth21.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.87Latest activity-pressure read.
Pressure change9.0%Four-week change in activity pressure.
Leadership-6.51Latest relative-leadership reading.
RS change15.3%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is inexpensive relative to peers.

Open full factor analysis
Factor week 02 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 97% Model confidence 92%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength86/100Blend of value, momentum, and quality. Underlying universe rank 15; rank 1 is best.
Value96/100Relative valuation strength. Underlying universe rank 5; rank 1 is best.
Quality67/100Profitability and accounting quality. Underlying universe rank 34; rank 1 is best.
Momentum20/100Medium-term price momentum. Underlying universe rank 81; rank 1 is best.
Growth16/100Revenue and earnings growth. Underlying universe rank 85; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework71/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
11.4x
Price divided by trailing earnings.
Price / sales
0.2x
Market value relative to trailing revenue.
EV / EBITDA
7.1x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
18.0%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
49.7%
Gross profit retained from each unit of revenue.
Operating margin
5.3%
Operating profit retained from revenue.
Free-cash-flow margin
10.1%
Free cash flow generated from revenue.
Return on invested capital
8.1%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
6.7%
Latest one-year revenue growth.
EPS growth
-40.2%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
31.8%
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
3.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

ARDT shows mixed options pressure with a 37/100 conviction score, put-call volume ratio of n/a, expected move of 31.2%, and Sharemaestro trend signal active.

Conviction37/100
Expected move31.2%
Put/call volume
Pressure10
Speculation0
Volatility96
Trend agreement91
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment48/100

Weighted news tone is neutral across 54 relevant articles.

7 positive · 38 neutral · 9 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings1dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
Options expected move31.2%Nearest-chain priced movement where available.
52-week drawdown-31.1%Distance below the 52-week high.
13-week volatility5.9%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2611 weeks finished lower.
Best week+10.6%Week of 3 Jul.
Worst week-9.8%Week of 20 Mar.
Latest week+0.3%Week of 31 Jul.

Shape of recent returns

Strong gains10
Modest gains4
Flat weeks1
Modest losses5
Sharp losses6
Recent vol5.9%13-week weekly-return volatility.
Base vol7.3%52-week weekly-return volatility.
Up/down split27/23Count of positive and negative weeks in the 52-week window.
Average skew4.8% / -4.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape36/100

Trend, activity pressure, participation, and risk combine to a 36/100 tape read.

 Indicator analysis54/100

Latest 12-week confirmation: trend 8/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.45; No reversal markers Next-Week ExpectancyNegative 44.18%

Next-week expectancy is negative with a 44.18% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors68/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 62; Small Cap Core rank 9 SVQF71/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 296.0 of 1014 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options58/100

ARDT shows mixed options pressure with a 37/100 conviction score, put-call volume ratio of n/a, expected move of 31.2%, and Sharemaestro trend signal active.

Mixed · Options-market disagreement · Expected move 31.2% Sentiment48/100

Weighted news tone is neutral across 54 relevant articles.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ardent Health, Inc. (ARDT) And Encourages Stockholders to Reach Out Insiders50/100

No recent insider transaction evidence is stored.

 Earnings1d

Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202610.67 USD0.3%9.41 USD12.95 USD0.87-6.512.9MOn
24 Jul 202610.64 USD4.8%9.34 USD12.97 USD0.89-6.032.6MOn
17 Jul 202610.15 USD0.7%9.30 USD13.00 USD0.91-11.232.7MOn
10 Jul 202610.08 USD-6.3%9.25 USD13.02 USD0.79-13.672.5MOn
3 Jul 202610.76 USD10.6%9.21 USD13.05 USD0.80-7.692.3MOn
26 Jun 20269.73 USD9.2%9.14 USD13.07 USD0.65-15.462.9MOn
19 Jun 20268.91 USD-4.7%9.11 USD13.11 USD0.45-25.262.9MOff
12 Jun 20269.35 USD7.7%9.11 USD13.15 USD0.42-21.813.0MOn
5 Jun 20268.68 USD-6.0%9.10 USD13.19 USD0.44-27.834.5MOn
29 May 20269.23 USD0.0%9.29 USD13.23 USD0.64-26.331.8MOff
22 May 20269.23 USD-8.6%9.47 USD13.27 USD0.86-26.341.9MOff
15 May 202610.10 USD-0.1%9.67 USD13.32 USD0.98-19.901.9MOff
8 May 202610.11 USD-0.4%9.82 USD13.35 USD0.92-20.782.6MOff
1 May 202610.15 USD4.7%9.95 USD13.38 USD0.72-19.692.1MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.